このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Virtual Reality Relaxation for Insomnia

2026年6月1日 更新者：Laval University

Virtual Reality Relaxation Intervention for Individuals With Insomnia

The goal of this clinical trial is to evaluate the feasibility, acceptability, and preliminary effects of a virtual reality (VR) relaxation intervention among adults aged 25 to 50 with insomnia disorder.

The main questions this study aims to address are:

  • Is a VR relaxation intervention feasible to implement and acceptable for individuals with insomnia?
  • Does the intervention reduce pre-sleep cognitive and somatic arousal?
  • Does the intervention improve sleep quality and sleep depth?
  • Can the intervention enhance overall sleep health and reduce symptoms of insomnia, anxiety, and depression?
  • Are these potential benefits maintained at a 3-month follow-up?

Participants will be randomly assigned to either the intervention group or a waitlist control group. Researchers will compare outcomes between groups to evaluate the impact of the intervention.

Participants will:

  • Complete online questionnaires at three time points (baseline, post-intervention, and 3-month follow-up) assessing sleep health, pre-sleep arousal, and symptoms of insomnia, anxiety, and depression
  • Take part in an in-person diagnostic interview at Université Laval to assess sleep and mental health status
  • Complete a daily online sleep diary for 8 weeks (2 weeks baseline, 4 weeks intervention, and 2 weeks post-intervention)
  • Engage in a 15-minute VR-guided meditation session each evening at home for 4 weeks
  • Wear a portable sleep monitor at home for 8 nights (4 nights baseline and 4 nights post-intervention)
  • Complete an acceptability questionnaire following the intervention

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The objective of this study is to evaluate the feasibility and acceptability of a virtual-reality relaxation intervention for individuals with insomnia disorder, and to assess its effects on pre-sleep arousal, sleep quality, mental health, and sleep depth. The intervention is expected to lead to high feasibility and acceptability, a reduction in cognitive and somatic pre-sleep arousal, a decrease in sleep latency, wake after sleep onset, and number of awakenings, as well as an increase in sleep efficiency. Reductions in insomnia severity, anxiety symptoms, and depressive symptoms are also expected. In addition, variables derived from the Odds Ratio Product (ORP)-a validated index of sleep depth ranging from 0 (deep sleep) to 2.5 (wake)-will be computed. It is anticipated that the intervention will increase the total time spent in deep sleep (ORP 0-0.5) and decrease gamma power (>35 Hz), alpha intrusion (i.e., the number of three-second epochs with alpha power > 30 µV²), and the time required for sleep depth to recover following an awakening (ORP-9).

An open-label, parallel-group, randomized controlled trial will be conducted to evaluate the feasibility, acceptability, and efficacy of the intervention. Thirty participants (15 women) aged 25 to 50 will be recruited following a diagnostic interview for insomnia (EDI-A) and psychiatric disorders (MINI). Insomnia severity (ISI), somatic and cognitive arousal (PSAS), and symptoms of anxiety (BAI) and depression (BDI-II) will be assessed using validated questionnaires. Participants will complete a daily sleep diary, and the Prodigy 2 Sleep Monitor, which enables home-based polysomnography (PSG), will be used to assess sleep quality and sleep depth. Feasibility outcomes (recruitment, retention, and adherence) and acceptability of the intervention, assessed through a self-reported questionnaire based on the Theoretical Framework of Acceptability, will complement the study measures.

The virtual-reality intervention consists of a 15-minute guided meditation adapted for sleep and combined with slow breathing (~6 breaths per minute) to promote immersive relaxation. Sessions will be performed in a seated position before bedtime, aligned with each participant's usual sleep schedule. The guided meditation, developed in collaboration with the McGill Mindfulness Research Lab, aims to enhance present-moment awareness and reduce negative sleep-related thoughts. The immersive environment was created in partnership with OVA, a Quebec-based company specializing in relaxing immersive environments, using visuals (starry night), ambient neutral soundscapes, and gender-neutral, accessible narration. Immersion will be delivered using a Meta Quest 3 headset configured to minimize exposure to blue light.

After providing informed consent and completing the diagnostic interview, eligible participants will complete psychological questionnaires, a two-week sleep diary, and four nights of home PSG at baseline [T1]. Participants will then be randomly assigned to the intervention group or the waitlist control group. The intervention group will complete the daily VR intervention for four weeks, after which both groups will undergo a second assessment [T2]. The waitlist group will then receive the VR intervention for four weeks, followed by its own post-intervention assessment. A three-month follow-up assessment will be conducted for both groups to evaluate whether the effects of the intervention are sustained over time.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Aged between 25 and 50 years
  • Experiencing difficulty initiating sleep, maintaining sleep, or early-morning awakenings at least three times per week for a minimum of three months
  • Residing within a 25-km radius of Université Laval

Exclusion Criteria:

  • Diagnosis of serious medical conditions (e.g., cancer, neurological disorders, chronic pain) or major psychiatric disorders
  • Conditions that could be exacerbated by virtual reality devices (e.g., epilepsy, eye disorders, dizziness, balance disorders)
  • Adverse effects related to virtual reality use (e.g., dizziness, nausea)
  • Currently using prescription or over-the-counter sleep aids
  • Engaged in night shifts or rotating shift work

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
他の：Waitlist control group
Participants in this arm will not receive the virtual-reality relaxation intervention after the two-week baseline period. Following baseline, they will continue their usual routines for four weeks without making any changes to their sleep or mental health practices. During this waiting period, they will complete the same assessments and daily sleep diary as the intervention group. At the end of the four-week waiting period, they will complete a post-waiting-period (second) assessment. After this assessment is completed, they will then be offered the same four-week virtual-reality relaxation intervention as the treatment group.
デバイス：Virtual reality relaxation intervention
A virtual reality (VR) intervention combining guided sleep-focused meditation and slow breathing will be used to provide an immersive relaxation experience. Each evening, participants will complete a 15-minute mindfulness meditation accompanied by visual animations designed to guide slow, paced breathing. The meditation content aims to cultivate present-moment awareness and facilitate the release of sleep-related negative thoughts and cognitive arousal. All sessions will be completed in a seated position before bedtime, aligned with each participant's typical sleep schedule. The immersive experience will be delivered using a Meta Quest 3 VR headset configured with a low-blue-light display mode.
他の名前：
  • VR relaxation intervention
実験的：Treatment
Participants in this arm will receive a four week virtual reality relaxation intervention following the two week baseline period. After baseline, they will engage in a 15 minute VR guided meditation session each evening at home for four weeks. At the end of the four week intervention, they will complete a post intervention assessment.
デバイス：Virtual reality relaxation intervention
A virtual reality (VR) intervention combining guided sleep-focused meditation and slow breathing will be used to provide an immersive relaxation experience. Each evening, participants will complete a 15-minute mindfulness meditation accompanied by visual animations designed to guide slow, paced breathing. The meditation content aims to cultivate present-moment awareness and facilitate the release of sleep-related negative thoughts and cognitive arousal. All sessions will be completed in a seated position before bedtime, aligned with each participant's typical sleep schedule. The immersive experience will be delivered using a Meta Quest 3 VR headset configured with a low-blue-light display mode.
他の名前：
  • VR relaxation intervention

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pre-Sleep Arousal
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Pre-Sleep Arousal Scale (PSAS) is a 16-item questionnaire that assesses symptoms of cognitive (e.g., racing thoughts, worry about not falling asleep) and somatic arousal (e.g., muscle tension, rapid heartbeat) experienced at bedtime. Participants rate the intensity of each symptom as they attempt to fall asleep using a five-point Likert scale ranging from 1 (not at all) to 5 (extremely). Higher scores on the scale indicate elevated levels of pre-sleep arousal.
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).

二次結果の測定

結果測定
メジャーの説明
時間枠
Insomnia severity
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Insomnia Severity Index (ISI) is a self-administered questionnaire used to assess the severity of insomnia. The ISI consists of seven items that evaluate the nature, intensity, and consequences of insomnia over the past month. The dimensions assessed include difficulties initiating or maintaining sleep (sleep onset latency, nighttime awakenings, early morning awakenings), dissatisfaction with sleep, the impact of sleep difficulties on daytime functioning, and the level of distress caused by these problems. Each item is rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely), yielding a total score ranging from 0 to 28. Interpretation thresholds are as follows: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate insomnia), and 22-28 (severe insomnia).
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Anxiety
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Beck Anxiety Inventory (BAI) will be used to assess participants' anxiety symptoms. The BAI consists of 21 items rated on a Likert scale from 0 (Not at all) to 3 (Severely - It bothered me a lot). The total score is calculated by summing the responses to all 21 items (0-7 points are considered to reflect a minimal level of anxiety; scores of 8-15 indicate mild anxiety; scores of 16-25 reflect moderate anxiety; and scores of 26-63 indicate severe anxiety).
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Depression
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Beck Depression Inventory - Second Edition (BDI-II) is a self-administered questionnaire designed to assess the severity of depressive symptoms. It consists of 21 items corresponding to various depressive symptoms, each rated on a four-point Likert scale from 0 (least severe) to 3 (most severe). The total score ranges from 0 to 63, with higher scores indicating greater severity of depressive symptoms.
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Sleep health
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Ru-SATED scale is a self-report questionnaire that assesses six dimensions of sleep health. It evaluates regularity (i.e., going to bed and waking up at about the same time each day), satisfaction with sleep, alertness (i.e., the ability to stay awake without dozing off during the day), timing (i.e., typically being in bed between 2:00 and 4:00 a.m.), efficiency (i.e., spending less than 30 minutes awake per night), and sleep duration (i.e., sleeping between 7 and 9 hours per night). Each dimension is rated on a five-point Likert scale from 0 (never) to 4 (always). The total score, obtained by summing the scores across the six dimensions, ranges from 0 to 24, with higher scores indicating better sleep health.
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Positive and negative emotions
時間枠：Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire used to assess the intensity of affective states. The instrument consists of 20 adjectives, with 10 describing positive affect and 10 describing negative affect. Participants rate, on a five-point Likert scale ranging from 1 (very slightly or not at all) to 5 (extremely), the extent to which they experience each emotion. A high score on the positive affect subscale reflects a state of high energy and pleasurable emotions, while a high score on the negative affect subscale indicates subjective distress involving multiple negative emotions.
Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Sleep characters recorded by sleep diary
時間枠：Baseline (Day 1), intervention (Weeks 1-4), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Participants will record sleep diaries each day duration the 4-week of intervention. Participants will complete 14-day sleep diaries at baseline before recruitment, end of intervention and 12 weeks after end of intervention. The following parameters extracted from the diary will be used for analysis: sleep latency (the time in minutes required to transition from wakefulness to sleep), number of awakenings (the count of nocturnal awakenings lasting more than 5 minutes), wake after sleep onset (the total time in minutes spent awake after initially falling asleep and before final awakening), and sleep efficiency (the proportion of total sleep time relative to time spent in bed).
Baseline (Day 1), intervention (Weeks 1-4), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
Sleep characters recorded by a portable sleep monitor
時間枠：Four consecutive nights at baseline and four consecutive nights at the end of the intervention (Week 4).
A portable sleep monitor (Prodigy 2 Sleep Monitor) will be used to collect objective measures of sleep quality. The following parameters recorded from the sleep monitor will be used for analysis: sleep latency (the time in minutes required to transition from wakefulness to sleep), number of awakenings (the count of nocturnal awakenings lasting more than 5 minutes), wake after sleep onset (the total time in minutes spent awake after initially falling asleep and before final awakening), and sleep efficiency (the proportion of total sleep time relative to time spent in bed).
Four consecutive nights at baseline and four consecutive nights at the end of the intervention (Week 4).

その他の成果指標

結果測定
メジャーの説明
時間枠
Acceptability of the intervention
時間枠：End of intervention (Week 4).
Participants will complete a brief acceptability questionnaire based on the Theoretical Framework of Acceptability (TFA). The questionnaire includes eight items assessing the following constructs: affective attitude, perceived burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs, and overall acceptability. All items are rated on a 5-point Likert scale ranging from 1 to 5, with response anchors varying by item (e.g., strongly disagree to strongly agree, or not at all appreciated to strongly appreciated). Higher scores indicate greater acceptability, except for items assessing perceived burden and opportunity costs, for which higher scores reflect greater burden or interference with other priorities.
End of intervention (Week 4).
Retention
時間枠：12 weeks after end of intervention (Week 16).
Retention is defined as the proportion of participants who complete the 4-week intervention and all associated assessments, including Baseline (Day 1), end of intervention (Week 4), and 12 weeks after end of intervention (Week 16).
12 weeks after end of intervention (Week 16).
Intervention adherence
時間枠：End of intervention (Week 4).
Intervention adherence is defined as the total number of intervention sessions completed over the 4-week intervention period.
End of intervention (Week 4).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Laval University

捜査官

  • スタディディレクター：Célyne H Bastien, PhD、Laval University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月1日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2026年2月17日

QC基準を満たした最初の提出物

2026年6月1日

最初の投稿 (実際)

2026年6月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月5日

QC基準を満たした最後の更新が送信されました

2026年6月1日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 2025-113/14-05-2025

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sets to be shared will include all de-identified individual participant data that underlie the results reported in future publications arising from this study. This will include de-identified questionnaire responses, sleep diary data, and objective sleep measures collected through the portable sleep monitor.

IPD 共有時間枠

Beginning 3 months after publication with no end date.

IPD 共有アクセス基準

Data will be made available upon reasonable request, and applicants will be required to submit a brief research proposal outlining the purpose of the data use. Access will be granted only after approval by the study investigators and completion of a data-sharing agreement ensuring appropriate use, confidentiality, and data protection. Data will be shared through secure, password-protected electronic transfer.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する